Enterprise Value
505.3M
Cash
749.6M
Avg Qtr Burn
-70.88M
Short % of Float
8.92%
Insider Ownership
2.14%
Institutional Own.
-
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
RLY-4008 (Lirafugratinib) Details Intrahepatic cholangiocarcinoma , Solid tumor/s, Cancer | Phase 1/2 Data readout | |
RLY-2608 + fulvestrant + ribociclib (triplet) Details Breast cancer, Cancer | Phase 1 Data readout | |
RLY-2608 + fulvestrant (doublet) Details Breast cancer, Cancer | Phase 1 Data readout | |
RLY-1971 (GDC-1971) Details Solid tumor/s, Cancer | Failed Discontinued |